IPATF News and Press, ImmunoPrecise Antibodies Ltd. From 04/19/20

Janssen Signs Collaboration with ImmunoPrecise Antibodies Johnson & Johnson ( JNJ ) reported that its biotech unit Janssen Research & Development has signed a new deal with ImmunoPrecise Antibodies Ltd. ( IPATF ). The new deal offers Janssen an exclusive access to an array of novel...

We caution that this news release is not making any express or implied claims that we have the ability to eliminate the SARS-CoV-2 virus at this time.  We further caution that we have not undertaken any clinical trials. VICTORIA , April 17, 2020 /PRNewswire/ - IMMUNOPRECISE A...

ImmunoPrecise Participates in Public Consensus Statement, from the WHO, on Collaboration for Developing a COVID-19 Vaccine Canada NewsWire VICTORIA, April 15, 2020 VICTORIA , April 15, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) ...

ImmunoPrecise Antibodies' ( OTCQB:IPATF ) subsidiary Talem Therapeutics has entered into a research license agreement with Janssen Research & Development, LLC, providing latter exclusive access to a panel of novel, monoclonal antibodies against an undisclosed target. More news o...

VICTORIA and CAMBRIDGE, MA , April 14, 2020 /PRNewswire/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC QB: IPATF), a global leader in therapeutic antibody discovery and development, announced that it, through its subsidiary Talem Therapeutics, has ente...

ImmunoPrecise Announces Appointment of Yasmina Noubia Abdiche, Ph.D., as Chief Scientific Officer Canada NewsWire VICTORIA, April 2, 2020 VICTORIA , April 2, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC QB: IPATF), a provider...

ImmunoPrecise Announces Extension of Debentures and Completion of Debt Settlement of Previously Issued Debentures Canada NewsWire VICTORIA, March 31, 2020 VICTORIA , March 31, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC QB: ...

We caution that this is still early stage research and development and is not making any express or implied claims that it has the ability to eliminate the SARS-CoV-2   virus at this time.  We further caution that we have not undertaken any clinical trials. VICTORIA , M...

New Approach Entails a Defined Antibody Combination Targeting Multiple Epitopes and Mechanisms of Viral Evasion VICTORIA , March 12, 2020 /PRNewswire/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC QB: IPATF), following its announcement to develop inn...

ImmunoPrecise Antibodies ( OTCQB:IPATF ): Q3 Net loss of C$0.63M. More news on: ImmunoPrecise Antibodies Ltd., Earnings news and commentary, , Read more ...